Mirikizumab: A New Therapeutic Option for the Treatment of Ulcerative Colitis.

Objective: To review the pharmacologic and clinical profile of mirikizumab in the treatment of moderate to severe ulcerative colitis (UC).
Data Sources: A PubMed search was performed from inception to December 2023 using keywords mirikizumab, interleukin-23 inhibitor , and UC . Information was also obtained from package inserts as well as published abstracts.
Study Selection and Data Extraction: Phase 3 studies plus relevant literature on mirikizumab pharmacologic and clinical profile were reviewed.
Data Synthesis: Mirikizumab approval was based on LUCENT-1 and LUCENT-2. In the phase 3 studies involving patients with moderate to severe UC, mirikizumab, when compared to placebo, resulted in clinical remission in a significantly higher proportion of patients in both the induction and maintenance phase. In addition, mirikizumab met the secondary endpoints of alternate definition of clinical remission, endoscopic remission, glucocorticoid-free clinical remission, histologic-endoscopic mucosal remission, and improvement in bowel urgency status, bowel-urgency remission, and maintenance of clinical remission. Common adverse events noted include infection (15.1%), injection-site reaction (8.7%), nasopharyngitis (7.2%), and headache (3.3%).
Relevance to Patient Care and Clinical Practice in Comparison to Existing Agents: Mirikizumab is the first selective interleukin 23 (IL-23) inhibitor approved for UC. Additional studies are required to determine how to position mirikizumab in both biologic-naïve and biologic-experienced patients with moderate to severe UC.
Conclusion: Mirikizumab provides a novel mechanism of action for the treatment of moderate to severe UC and is another welcomed treatment advance in the treatment arsenal, providing a more selective mechanism of action while maintaining a comparable safety profile.
Competing Interests: Declaration of Conflicting InterestsThe authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: DC has served on the speaker bureau for Janssen Pharmaceuticals and has served as a consultant to Bristol Myers Squibb, and Boehringer Ingelheim, Abbvie, Janssen Pharmaceuticals. SB has served as a consultant to Bristol Myers Squibb, Prometheus Laboratories, Pfizer, AbbVie, and Boehringer Ingelheim. HS has no conflicts of interest to declare.